Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia

Asadi, Farrokh; Farraj, Mohammad A.; Sharifi, Rohollah; Malakouti, Sadegh; Antar, Salah; Kukreja, Subhash C.

doi:10.1016/s0046-8177(96)90344-5

Cited by 71 publications

(58 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lymph node metastases exhibit similar levels of PTHrP expression to those of poorly differ- PTHrP and receptor in prostate cancer and bone metastases AAG Bryden et al entiated primary tumours (Asadi et al, 1996). In this study mRNA for PTHrP was detected in all 14 primary prostate tumours, although expression was heterogeneous in four cases.…”

Section: Discussionmentioning

confidence: 43%

“…In primary prostate cancer PTHrP staining intensity increases with tumour grade (Asadi et al, 1996), and in vitro cell line studies have suggested that it may be a significant autocrine growth factor (Iwamura et al, 1994a). Drawing on the work in breast cancer and the parallels between the two tumours, it has been suggested that PTHrP may be a potential factor in the pathogenesis of prostate cancer bone metastases (Guise, 1997).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases

et al. 2002

View full text Add to dashboard Cite

Parathyroid hormone-related peptide is a regulatory protein implicated in the pathogenesis of bone metastases, particularly in breast carcinoma. Parathyroid hormone-related peptide is widely expressed in primary prostate cancers but there are few reports of its expression in prostatic metastases. The aim of this study was to examine the expression of parathyroid hormonerelated peptide and its receptor in matched primary and in bone metastatic tissue from patients with untreated adenocarcinoma of the prostate. Eight-millimetre trephine iliac crest bone biopsies containing metastatic prostate cancer were obtained from 14 patients from whom matched primary tumour tissue was also available. Histological grading was performed by an independent pathologist. The cellular location of mRNA for parathyroid hormone-related peptide and parathyroid hormone-related peptide receptor was identified using in situ hybridization with 35 S-labelled probe. Expression of parathyroid hormone-related peptide and its receptor was described as uniform, heterogenous or negative within the tumour cell population. Parathyroid hormonerelated peptide expression was positive in 13 out of 14 primary tumours and in all 14 metastases. Receptor expression was evident in all 14 primaries and 12 out of 14 metastases. Co-expression of parathyroid hormone-related peptide and parathyroid hormone-related peptide receptor was common (13 primary tumours, 12 metastases). The co-expression of parathyroid hormone-related peptide and its receptor suggest that autocrine parathyroid hormone-related peptide mediated stimulation may be a mechanism of escape from normal growth regulatory pathways. The high frequency of parathyroid hormone-related peptide expression in metastases is consistent with a role in the pathogenesis of bone metastases.

show abstract

Section: Discussionmentioning

confidence: 43%

mentioning

confidence: 99%

Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases

et al. 2002

View full text Add to dashboard Cite

show abstract

“…In a small number of lymph node metastases high levels of PTHrP expression have been found. 25 The observed expression of PTHrP was comparable to those seen in poorly differentiated primary tumours.…”

Section: Discussionmentioning

confidence: 55%

“…These data correlate well with the findings of Iddon et al 26 where 7/14 prostatic bone metastases expressed PTHrP, although true comparison is difficult as Iddon describes neither the tumour differentiation nor their treatment status (untreated, hormone manipulated or hormone refractory). Conflicting with these results are those of Asadi 25 and Lee, 27 who showed high levels of PTHrP expression in small numbers of metastases. It may be that within the limited size of this series there is a chance of a disproportion in the number of well and moderately differentiated tumours when compared to untreated prostatic metastases in general.…”

Section: Discussionmentioning

confidence: 81%

Parathyroid hormone-related peptide: expression in prostate cancer bone metastases

Bryden

Islam

Freemont

et al. 2002

Prostate Cancer P D

View full text Add to dashboard Cite

Parathyroid hormone-related peptide (PTHrP) is a regulatory protein associated with cell growth in non-osseous tissues and with osteoclast stimulation in bone. It has been implicated in the pathogenesis of bone metastases, particularly in breast carcinoma. PTHrP is widely expressed in primary prostate cancers, but there are few reports of its expression in prostatic metastases. The aim of this study was to examine the expression of PTHrP in bone metastases from patients with untreated adenocarcinoma of the prostate. Ten bone biopsies containing metastatic deposits of untreated prostatic cancer were identified. These were immunohistochemically stained for PTHrP using a murine monoclonal antibody (PTHLP[Ab1]) and the streptavidin -biotin complex technique. Intensity of staining for PTHrP was graded by two observers. In total, PTHrP expression was positive in 5/10 specimens. This was graded as moderate in four and weak in one. In those specimens with positive staining, the expression varied between cells. There was no obvious association between expression of PTHrP and tumour differentiation. PTHrP is expressed in prostatic bone metastases and may have a role in their pathogenesis and pathophysiology. However, expression is not universal.

show abstract

“…The PTHrP is believed to be a mediator for 70% of breast and prostate cancer: (1) higher PTHrP expression in prostatic dysplasia (prostate intraepithelial neoplasia) than in normal prostate epithelium and (2) higher PTHrP expression in prostate carcinoma than in benign hyperplasia suggests that there are promalignant or proliferative effects of PTHrP that participate in the pathophysiology of prostate cancer. [6][7][8] In normal breast cells, similarly to PTH release, the secretion of PTHrP is inhibited by increase in the Ca 2+ concentra- ) appears to be sufficient to elicit apoptosis.…”

Section: Role Of Pth-dependent Calcium Homeostasis In Different Endocmentioning

confidence: 99%

Hormonal Regulation of Calcium Signaling in Endocrine Cancers

George¹,

Changtoo²,

Singh³

et al. 2014

World Journal of Endocrine Surgery

View full text Add to dashboard Cite

The calcium ion (Ca 2+ ) plays a fundamental role in a number of physiological functions including bone formation, muscle contraction, secretion, enzyme cofactor, stabilization of membrane potentials, blood coagulation, etc. Calcium is homeostatically regulated by hormones that determines calcium balance within the body. The hormones PTH, 1,25-(OH)2D3 and calcitonin are altered in endocrine cancers which are in turn regulated by calcium. The main focus of this review is how hormones can regulate calcium homeostasis in endocrine cancers.

show abstract

Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia

Cited by 71 publications

References 17 publications

Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases

Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases

Parathyroid hormone-related peptide: expression in prostate cancer bone metastases

Hormonal Regulation of Calcium Signaling in Endocrine Cancers

Contact Info

Product

Resources

About